Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 20;13(22):5827.
doi: 10.3390/cancers13225827.

Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions

Dipenkumar Modi  1 , Bindu Potugari  2 , Joseph Uberti  1
Affiliations
Review

Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions

Dipenkumar Modi et al. Cancers (Basel). .

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease. B-cell receptor (BCR) pathway is essential for malignant B-cell growth, survival, and proliferation. Various immune cells, including T-cells and macrophages in the tumor microenvironment (TME) contribute to tumor cell survival and pathogenesis of chemo-resistance. The presence of many targets on the malignant B-cells and in the TME has led to emergence of novel therapeutic agents. Stem cell transplant is the oldest treatment modality leveraging immune system in DLBCL. Subsequently, CD20 targeting monoclonal antibody and chimeric antigen receptor (CAR) T-cell therapy changed the treatment landscape of DLBCL. Recently, multiple novel immunotherapeutic agents have been added in the armamentarium for the management of DLBCL, and many are under development. In this review article, we will review latest updates of immunotherapeutic agents in the management of DLBCL.

Keywords: CAR T-cell therapy; allogeneic stem cell transplant (alloSCT); autologous stem cell transplant (autoSCT); bispecific T-cell engager antibody; checkpoint inhibitors; diffuse large B-cell lymphoma (DLBCL); immunotherapy; nivolumab; pembrolizumab.

PubMed Disclaimer

Conflict of interest statement

Dipenkumar Modi serves in the advisory board in the MorphoSys and Seagen.

Figures

Figure 1
Figure 1
Overview of the interaction between malignant B-cells and other immune cells in the tumor microenvironment, and the therapeutic targets in diffuse large B-cell lymphoma. CAR: Chimeric antigen receptor; BiTE: Bispecific T-cell engager; SIRP: Signal regulatory protein.
See this image and copyright information in PMC

References

    1. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., et al. Distinct types of diffuse large B-cell lym-phoma identified by gene expression profiling. Nature. 2000;403:503–511. doi: 10.1038/35000501. - DOI - PubMed
    1. Lenz G., Wright G., Dave S., Xiao W., Powell J., Zhao H., Xu W., Tan B., Goldschmidt N., Iqbal J., et al. Stromal Gene Signatures in Large-B-Cell Lymphomas. N. Engl. J. Med. 2008;359:2313–2323. doi: 10.1056/NEJMoa0802885. - DOI - PMC - PubMed
    1. Scott D.W., Mottok A., Ennishi D., Wright G.W., Farinha P., Ben-Neriah S., Kridel R., Barry G.S., Hother C., Abrisqueta P., et al. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Bi-opsies. J. Clin. Oncol. 2015;33:2848–2856. doi: 10.1200/JCO.2014.60.2383. - DOI - PMC - PubMed
    1. Cuccuini W., Briere J., Mounier N., Voelker H.U., Rosenwald A., Sundstrom C., Cogliatti S., Hirchaud E., Ysebaert L., Bron D., et al. MYC+ diffuse large B-cell lym-phoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood. 2012;119:4619–4624. doi: 10.1182/blood-2012-01-406033. - DOI - PMC - PubMed
    1. Scott D.W., King R.L., Staiger A.M., Ben-Neriah S., Jiang A., Horn H., Mottok A., Farinha P., Slack G.W., Ennishi D., et al. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood. 2018;131:2060–2064. doi: 10.1182/blood-2017-12-820605. - DOI - PMC - PubMed

LinkOut - more resources